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Summary The paracrine influence of prostatic stroma on the proliferation of prostatic epithelial cells was
investigated. Stromal cells from the human prostate have previously been shown to inhibit anchorage-
dependent as well as anchorage-independent growth of the prostatic tumour epithelial cell lines PC-3 and
LNCaP. Antiproliferative activity, mediated by a diffusible factor in the stromal cell conditioned medium, was
found to be produced specifically by prostatic stromal cells. In the present study the characteristics of this
factor were examined. It is demonstrated that prostate stroma-derived inhibiting factor is an acid- and
heat-labile, dithiothreitol-sensitive protein. Although some similarities with type beta transforming growth
factor (TGF-P)-like inhibitors are apparent, evidence is presented that the factor is not identical to TGF-J3 or
to the TGF-p-like factors activin and inhibin. Absence of TGF-P activity was shown by the lack of inhibitory
response of the TGF-p-sensitive mink lung cell line CCL-64 to prostate stromal cell conditioned medium and
to concentrated, partially purified preparations of the inhibitor. Furthermore, neutralising antibodies against
TGF-PI or TGF-P2 did not cause a decline in the level of PC-3 growth inhibition caused by partially purified
inhibitor. Using Northern blot analyses, we excluded the involvement ofinhibin or activin. It is concluded that
the prostate stroma-derived factor may be a novel growth inhibitor different from any of the currently
described inhibiting factors.
Keywords: stromal-epithelial interactions; prostate cancer; benign prostatic hyperplasia; transforming growth
factor beta; growth inhibitor
Control of cellular proliferation in the prostate involves a
complex interaction of different cell types with soluble pep-
tide growth factors, (steroid) hormones and constituents of
the extracellular matrix. It is likely that the array of peptide
factors which play a role in the regulation of cell prolifera-
tion and differentiation affects these processes through both
positive and negative control mechanisms. The direct impor-
tance of embryonic messenchyme as a mediator of the
androgen-induced prostatic ductal morphogenesis, epithelial
growth, secretory cytodifferentiation and function has been
demonstrated convincingly (Cunha et al., 1987). Subse-
quently, it was shown that these interactions may have
retained their integral role in the adult prostate (Cunha et al.,
1987; Chung et al., 1991a). It is an intriguing observation
that, upon maturation, accessory sexual organs reach a
typical size and weight which is characteristic for that partic-
ular organ (Cunha et al., 1987). Likewise, administration of
testosterone to androgen-deprived rats restores the size of the
prostate to its normal precastration level without inducing
overgrowth, even after prolonged administration (Cunha et
al., 1987). At that stage, epithelial cell proliferation is low
and in balance with cell death (Isaacs, 1984). Several inves-
tigators have been searching for the molecular basis of this
homeostatic constraint mechanism that curtails further inc-
rease in cell number once the gland has reached its predeter-
mined size.
So far, TGF-P is the only well-kiown epithelial cell growth
inhibitor that has been identified in the prostate (Barnard et
al., 1990; Wilding, 1991). Its presence in prostatic tissue has
been demonstrated by Northern blot analyses (Kyprianou
and Isaacs, 1989; Mori et al., 1990), and elevated levels of
TGF-P have recently been associated with prostate cancer
(Thompson et al., 1992). In vitro studies have implicated
TGF-,B as a potent inhibitor of prostatic epithelial cells, both
normal and malignant (McKeehan and Adams, 1988; Wil-
ding et al., 1989; Goldstein et al., 1991). As these cells have
been shown to secrete TGF-P themselves (Ikeda et al., 1987;
Danielpour et al., 1989), an autocrine mode of action is
suggested. In vivo, TGF-P has been shown to act mainly on
the rate of prostatic glandular cell death, while its expression
appeared to be under negative androgenic regulation (Mar-
tikainen et al., 1990). Since these determinations were per-
formed on whole tissue homogenates, it is still not clear
whether TGF-P is produced by the stroma or the epithelium.
A recent immunohistochemical study (Truong et al., 1993)
demonstrated immunoreactivity to TGF-P1I antibodies in
epithelial and mesenchymal cells, but unfortunately this kind
of experiment does not reveal the site of synthesis of the
proteins. However, the observation that rat and human pros-
tatic epithelial cells grown in vitro can proliferate in serum-
free medium without the presence of androgens (McKeehan
et al., 1984; Peehl and Stamey, 1986; Nishi et al., 1988), while
androgen ablation in vivo induces a marked regression of the
glandular epithelium (Isaacs, 1984), indicates a major role for
the stroma in the negative control of epithelial cell prolifera-
tion. A number of investigators have studied stromal-
epithelial interactions in the prostate in vitro, but their
reports mainly focused on the mitogenic influence of the
stroma (Sherwood et al., 1988; Kabalin et al., 1989; Djakiew
et al., 1991; Gleave et al., 1992; Sherwood et al., 1992). No
further reports from other groups have been published on
stromally derived epithelial cell growth inhibitors in the adult
prostate. Remarkably, all studies demonstrating stromal
stimulation of prostatic epithelial cell growth were performed
under serum-free conditions. However, Kirk et al. (1981)
showed an inhibition of PC-3 cell growth by lung fibroblasts,
using a serum-dependent soft-agar assay. Using a similar
assay, we previously observed inhibition of the clonal growth
ofprostatic carcinoma cell lines PC-3 (hormone independent)
and LNCaP (hormone responsive) by co-cultured prostatic
stromal cells (Kooistra et al., 1991). Rowley and Tindall
(1987) reported growth inhibition of a bladder carcinoma cell
line by medium conditioned by urogenital sinus explants in
the presence of 5% fetal calf serum (FCS) and 5% (synthetic)
Nu-serum. Later, it was shown that antiproliferative activity
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was produced by a fibroblastoid cell strain derived from
urogenital sinus mesenchyme (Rowley, 1992a). Although cells
were shown to express urogenital sinus-derived growth
inhibitory factor (UGIF) activity for up to 5 -7 days in
unsupplemented Dulbecco's Modified Eagle Medium
(DMEM; changed daily), cultures failed to survive under
these non-physiological conditions. The presence of the
UGIF was tested in a serum-containing assay. Using
physicochemical, biological and immunological methods
UGIF was demonstrated to differ from known growth
inhibiting factors, including TGF-P. Using the same bioassay,
however, no activity could be found in a chemically defined
medium developed for long-term culture that was condi-
tioned in exactly the same manner. Only addition of steroid
hormone caused the fibroblastoid cells to produce inhibiting
activity that ultimately was identified as being caused by
activated TGF-P and not by UGIF (Rowley, 1992b).
Although a serum-free environment is ideal for testing as well
as identification of regulatory peptides, certain information
may be lost, as suggested by the findings reported by Kirk et
al. (1981) and Rowley (1992b), and the results presented here.
The prostatic stromal cell-derived antiproliferative activity we
found was mediated by a diffusible factor present in serum-
containing conditioned medium (CM) of stromal cells from
neoplastic lesions of (adult) prostates (Konig et al., 1987;
Kooistra et al., 1991, 1995a). In the present report we show
that this factor is different from TGF-P, its related peptides
inhibin and activin, and from other inhibitors previously
described. Awaiting further identification, we provisionally
and operationally refer to this putative inhibiting factor as
'Prostate-derived epithelium inhibiting factor' (p-EIF).
Materials and methods
Stromal cell cultures
Surgically obtained tissue specimens from histologically pro-
ven benign prostatic hyperplasia (BPH) and prostatic car-
cinoma (PC) were cut into pieces (approximately 1 mm
x 2 mm), and placed in 35 mm Petri dishes (Nunc) contain-
ing 1.5 ml of basal medium: Earle's minimum essential
medium (Gibco Europe, Breda, The Netherlands) supp-
lemented with 10% FCS (Biological Industries, Beth
Haemak, Israel), 2 mM glutamine, penicillin and strep-
tomycin (all from Gibco Europe). Cultures were maintained
in a humidified incubator at 37°C in 5% carbon dioxide/air.
Medium was replaced twice a week. The initial halo of
epithelial cells grown from these explant cultures became
overgrown with fibroblast-like cells within several weeks.
Subsequently, cells were detached by trypsinisation (0.05%
trypsin in 0.02% EDTA) (Gibco Europe) and split in a 1:3
ratio every 2-3 weeks. In order to minimise the number of
epithelial cells in our cultures we used only prostatic stromal
cells of passage number 4-9 in this study. Using the monoc-
lonal antibody NCLSD3 (Organon, Oss, The Netherlands)
reacting with keratin 8, 18 and 19, we found that the number
of positive cells in these cultures (BPH as well as PC) never
exceeded 5%, indicating that nearly all cells were of non-
epithelial origin (Kooistra et al., 1995b).
Cell lines
The prostatic carcinoma cell line PC-3, obtained from Flow
Laboratories (Irvine, UK) and maintained in basal medium,
was used between passage numbers 35 and 45. LNCaP-FGC
cells (used at passage number 65-70), originally made
available to us by Dr J Horoszewicz (Buffalo, USA), were
cultured in RPMI-1640 (Gibco Europe) supplemented with
10% FCS, glutamine and antibiotics. The mink lung cell line
MLCCL 64 (Holley et al., 1983) was obtained from the NIH
(Frederick, MO, USA) and cultured in DMEM-high glucose
(Gibco Europe) supplemented with 7.5% FCS and anti-
biotics. All cultures were shown to be free of mycoplasma
contamination by staining with Bisbenzimide (Hoechst dye
33258) obtained from Sigma (St Louis, MO, USA).
Collection ofconditioned medium
Prostatic stromal cell conditioned medium (approximately
0.2 ml cm-2) was collected twice a week from confluent
monolayers (approximately 60-100 x 03 cellscm-2). After
centrifugation (6000g, 20 min, 4°C), CM was stored at
-20°C until further use.
Concentration andpartialpurification
CM of different passages was pooled and fractionated by
ammonium sulphate precipitation. This was performed
through a stepwise increase in the level of saturation by
adding solid ammonium sulphate (Sigma) to the medium at
0°C under continuous stirring (Dixon, 1953). At every 10%
rise the solution was centrifuged (10000g, 4°C, 20min) and
the pellet dissolved in PBS (Gibco Europe). Samples from
supernatant and pellet were extensively dialysed (Spectrapor
3, cut-off 3500 dalton; Spectrum Medical, Los Angeles, CA,
USA) at 4°C against PBS and MEM successively, and stored
at -20°C after sterilisation through a 0.451 m membrane
(Schleicher & Schuell, 's-Hertogenbosch, The Netherlands).
Osmolarity was checked to be 275-325 mosmol, using a
Roebling osmometer (Vogel, Giessen, Germany). Using this
'first-step' purification procedure, 75% ofcontaminating pro-
tein could be discarded (Kooistra et al., 1995a).
Physicochemical characterisation
Concentrated and partially purified CM was diluted with
PBS to a protein concentration of 2 mgml-'. Trypsin sen-
sitivity was tested by incubation with trypsin (T 8003, Sigma)
at a concentration of 100 ltg ml-' for 2 h at 37°C, followed
by the addition of soybean trypsin inhibitor (STI) (T 9003,
Sigma) at a final concentration of 200ILgml-'. As a control,
equal amounts of trypsin and STI were preincubated in PBS
for 30 min at 20°C and subsequently incubated with the
samples for an additional 2 h at 37°C. The reducing agent,
dithiothreitol (DTT) (Sigma) was added to each sample at a
final concentration of 130 mM. Incubation was performed on
a rocker platform for 60 min at 20°C. Control samples were
incubated without DTT. Acid treatment was performed by
acidifying samples to pH 1.5 with 2 M hydrochloric acid for
1 h at 20°C, then neutralising by 2M sodium hydroxide.
Control samples were adjusted to the same volume as test
samples, using 2M sodium chloride. Heat sensitivity was
tested in the presence of 100 mM Hepes, at 56°C for 30min,
or at 100°C for 3 min. Samples were incubated in closed glass
tubes in a rocking water bath. Controls for all tests men-
tioned above were obtained by similar treatment of basal
medium (diluted to a protein concentration of 2 mgml-').
After incubation, all samples were subsequently dialysed at
4°C against PBS and MEM, and sterilised by filtration over a
0.45jsm pore membrane. For determination of growth inhibi-
tion (MTT test), 180jil of sample and 20,ul of FCS were
added at day 0. Stability at a range of temperatures was
tested by heating aliquots of CM for 5 min at indicated
temperatures. In order to keep the pH at the same level
throughout the incubation, Hepes was added to a concentra-
tion of 100 mM. As a control, basal medium and serum-free
basal medium were treated likewise. Samples were subse-
quently dialysed against PBS and MEM and the inhibition of
cell growth was tested after sterile filtration, using the MTT
test or the [3H]thymidine incorporation assay.
Neutralisation tests
TGF-i1 from human platelets and TGF-P1 neutralising
polyclonal antibodies raised in rabbits were prepared at the
Hubrecht laboratory, Utrecht, The Netherlands (Van den
Eijnden-Van Raaij et al., 1990a). Porcine platelet TGF-P2
was obtained from Sandoz (Basle, Switzerland), while TGF-P2-specific (neutralising) antibodies, also from rabbit, were
purchased from R&D Systems (Minneapolis, MN, USA).
Concentrated, semipurified inhibitor was diluted to 1 mg
ml-', preincubated with antibody (30 Lg ml-') for 1 h at
37°C and subsequently added to wells containing PC-3 cells
(MTT test). Controls were obtained by preincubation with
non-immune serum IgG. Activity of immune serum IgG was
tested by incubation of TGF-P11 (10 ngml-' in MEM, 0.1%
bovine serum albumin) with equal amounts of antibody.
Tests with TGF-P2 antibodies were performed with 80 lg
ml-' antibody, and for controls 20 ngml' TGF-P2 was
used. Optimal amounts of antibody (saturable activity) were
determined by incubating inhibitor with different amounts of
antibody.
Protein determination
Protein concentrations were measured with the Bio-Rad Pro-
tein Assay Kit (Bio-Rad Labs, Veenendaal, The Nether-
lands). A 1:1 mixture of the albumin and globulin solutions
was used as a standard.
Growth inhibition assays
MTT test Inhibition of cell growth was determined by
means of a colorimetric assay based on the reduction of a
tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT), to a coloured formazan product
(maximum absorption at 560 nm) by mitochondrial enzymes
present only in living, metabolically active cells (Romijn et
al., 1988). Cells were harvested by trypsinisation, resuspended
in fresh culture medium, and plated in a volume of0.1 ml per
well in 96-well microtitre plates (Costar). Inoculum: PC-3,
2000 per well; LNCaP, 5000 per well; MLCCL-64, 1500 per
well. The next day (day 0), 0.1 ml of sample was added,
giving a 50% dilution of the sample. At day 3, 30 lA of a
5 mgml-' solution of MTT (Sigma) in PBS was added to
each well. After a 4 h incubation at 37'C in 5% carbon
dioxide/air, the medium was carefully sucked off and the
purple dye was dissolved in 0.1 ml of dimethylsulphoxide
(DMSO) (Merck, Darmstadt, Germany). Plates were placed
on a plate shaker for 5 min, and the absorbance at 560 nm
was read using a Flow Titertek Multiskan plate reader.
Unless otherwise stated, eight replicate wells were used for
each sample. Wells containing medium but no cells served as
blanks. Results are expressed as percentage of maximal
growth from day 0, obtained in fresh basal medium. To
determine the number of cells at this point, one extra plate
was measured at day 0.
[3H]Thymidine incorporation This was measured using 5000
MLCCL-64 cells per well in 24-well plates (Nunc). The mink
lung carcinoma cell line CCL-64 is known to be very sen-
sitive to TGF-ps (Tucker et al., 1984; Danielpour et al.,
1989). Cells were plated on day 1 in 1 ml of DMEM (Gibco
Europe) supplemented as described. After 4 h, 0.1 ml of sam-
ple was added. At day 3, 0.5 ,Ci of [3H]thymidine (Amer-
sham, UK) in 0.1 ml of Ham's F12 medium was added to
each well and plates were incubated for another 16 h.
Monolayers were washed four times with PBS, then fixed in
methanol for 15 min at room temperature and dried in air.
Cells were then dissolved in 1 ml of 1 M sodium hydroxide
(30min, 37°C), transferred to a scintillation vial and radio-
activity was counted.
Northern blot analyses
After removal of culture medium, stromal cells were frozen
in solid carbon dioxide/ethanol, and stored at -80°C. Total
RNA was isolated using an acid guanidinium thiocya-
nate-phenol-chloroform extraction procedure (Chomczyn-
ski and Sacchi, 1987). Of each sample, 40gtg of total RNA
was denatured in formamide/formaldehyde at 55°C for
15 min before electrophoresis on denaturing 1% agarose/
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formaldehyde gels. After electrophoresis, RNA was blotted
on Hybond N+ (Amersham, UK) by diffusion. Filters were
baked for 2 h at 80°C, and subsequently prehybridised for
2 h at 42°C in a hybridisation solution containing 50% for-
mamide, 9% (w/v) dextran sulphate, 10 x Denhardt's [1 x-
Denhardt's contains 0.02% (w/v) Ficoll, 0.02% (w/v)
polyvinylpyrrolidone, 0.02% (w/v) bovine serum albumin],
5 x SSC (1 x SSC contains 0.15 M sodium chloride, 0.015 M
sodium citrate, pH 7.0), 10 mM sodium phosphate (pH 6.8),
and lOO1lgmlm' denatured salmon sperm DNA. Probes for
hybridisation were labelled with 32P by random oligo-
nucleotide labelling (Feinberg and Vogelstein 1983), de-
natured in boiling water for 5 min and added directly to the
hybridisation solution. Following 48 h of hybridisation at
42°C, filters were washed to a final stringency of 0.1 x SSC,
0.1% SDS, 50°C. Filters were exposed to Amersham
Hyperfilm-MP (Amersham, UK) at -70°C for various leng-
ths of time, using an intensifying screen. Probes used were
described by Esch et al. (1987) and Derynck et al. (1985). As
a control for equal amounts of RNA, a hamster actin cDNA
probe was used.
Statistical analysis
The statistical significance of differences between individual
treatment groups was calculated using Student's t-test.
Differences were considered statistically significant if the two-
tailed P-value was smaller than 0.05.
Results
Effect ofprostatic stromal cell CM andpartiallypurified
inhibitor on the growth ofprostatic tumour epithelial cells
We previously reported the inhibition of anchorage-
independent growth of the hormone-insensitive prostatic car-
cinoma cell line PC-3, as well as the hormone-responsive
prostatic carcinoma cell line LNCaP, by co-cultured prostatic
stromal cells (Kooistra et al., 1991). Figure 1 shows that CM
from prostatic stromal cells was capable of inhibiting the
growth of PC-3 cells in monolayer cultures up to approx-
imately 50%. Growth in PBS was significantly better than
that found in dialysed CM, indicating that the inhibition was
not due to depletion of nutrients or of growth-promoting
factors. Concentration and partial purification of CM
resulted in a potent solution reaching inhibition levels up to
80-90% at protein concentrations less than 5 mgml'. In a
comparative experiment, bovine serum albumin was shown
to interfere with cell growth only at higher concentrations,
demonstrating that the observed inhibition of semi-purified
inhibitor was not merely due to a high protein content. As a
control, basal medium and CM from skin fibroblasts were
E
s
Time (days)
Figure 1 Inhibition of PC-3 cell growth by prostatic stromal cell
CM. The y-axis gives the absorbance at 560 nm as determined by
the MTT test (see Materials and methods). All samples were
dialysed against basal medium without FCS. 0, Basal medium;
0, PBS; A, conditioned medium. Error bars = s.d.Stromalinhibiton ofprostabic epithelium
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fractionated in a similar way. No inhibiting activity was
found in these preparations. As can be seen in the dilution
curves in Figure 2, LNCaP cells are almost equally sensitive
to the antiproliferative activity as PC-3 cells. Preliminary
studies on primary cultures of BPH and prostatic carcinoma
epithelium showed these cells to be responsive too.
Biochemical characterisation
The inhibitory activity of partially purified p-EIF prepara-
tions was tested under different conditions in an attempt to
elucidate the nature of the putative inhibitor. The fact that
the inhibitor could be precipitated by ammonium sulphate
already suggested that a protein is involved. This idea was
supported by the observation that trypsin digestion resulted
in a statistically significant reduction in inhibitory activity
(Figure 3a). Treatment with DTT resulted in a complete
disappearance of activity (Figure 3b), demonstrating the
PC-3 LNCaP
Figure 2 Serial dilutions ofpartially purified inhibitor on human
prostatic carcinoma cell lines PC-3 and LNCaP, as determined by
the MTT test. Growth is given as percentage of growth obtained
in fresh basal medium. Error bars = s.d. A, 2.5 mgml-'; B,
0.625mgml1'; C, 0.156mgmlh'; D, 0.039mgml '; E,
0.010 mg ml'.
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requirement of S-S bridges for biological activity. Acid
treatment of partially purified inhibitor significantly reduced
the inhibiting activity (Figure 3c). Surprisingly, treatment of
basal medium resulted in the generation of inhibiting activity,
which may explain the observation that inactivation of the
stromal cell-derived inhibitor did not restore growth to
100%, although inactivation of growth-promoting substances
might also have contributed to this effect. Figure 3d shows
that treatment of the concentrated fraction of inhibitor at
56°C for 30 min resulted in a small, but statistically
significant, decrease in antiproliferative activity. This obser-
vation suggested p-EIF to be heat labile. However, heating at
100°C restored the inhibiting activity to levels found before
treatment, while similar effects were seen after heating basal
medium. In order to look at this aspect more carefully, we
performed similar experiments on CM, using a wider range
of temperatures. The increasing levels of inhibition generated
in basal (serum-containing) medium by treatment at higher
temperatures are clearly demonstrated (Figure 4a). However,
a tendency of the stromal cell inhibitor to lose its inhibiting
capacity (observed after heating at 56°C and 70C) was
noted.
Northern blot analysis
To explore the possibility that TGF-P or TGF-13-like subs-
tances were the active component in stromal cell-derived
medium, Northern blot analyses were used to examine the
possible expression of mRNAs coding for these compounds
in stromal cells. Confluent cultures of stromal cells from
BPH, Wilms' tumour and normal kidney tissue were used.
TGF-,1I mRNA was shown to be present in all four cultures
a
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Figure 3 Physicochemical characterisation of prostatic stromal
cell derived inhibitor partially purified by ammonium sulphate
precipitation. Inhibitor (P) and basal medium (BM) were treated
with (a) trypsin, (b) dithiothreitol (DTT), (c) acid (pH 1.5) or (d)
heat (56°C and 100C). C (control), initial solution of inhibitor or
basal medium; T/S, trypsin preincubated with soybean trypsin
inhibitor (for details see Materials and methods). Bars = s.d.
*Significantly different from control.
0 3756708090100
Temperature (°C)
Figure 4 Induction ofinhibitory activity by heat exposure. Sam-
ples of CM, basal medium (BM) including 10% FCS, and basal
medium without serum (M-) were subjected to the temperatures
indicated. Activity of samples was tested (a) on PC-3 cells using
the MTT test (0, BM; 0, CM; 0, M-) and (b) in the TGF-P
assay on MLCCL-64 cells measuring [3H]thymidine incorporation
(0, CM; *, BM), showing active TGF-,B after heating at higher
temperatures. For comparison, the curve for basal medium tested
on PC-3 cells is shown again in b. Growth is given as the
percentage of control cultures grown in fresh basal medium.
Levels of significance were calculated in relation to the untreated
CM. *P<0.05, **P<0.01. Bars = s.d.
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Iinvestigated (Figure 5). However, since stromal cell CM from
Wilms' tumour and normal kidney tissue did not inhibit
PC-3 cell growth (Kooistra et al., 1995a), this does not
necessarily imply that sufficient amounts of (active) TGF-P
are secreted into the medium. We also examined the involve-
ment of activin and inhibin in cultured prostatic stromal
cells. As shown in Figure 5, no P-A/B chain or a-chain
mRNAs were detected in prostate derived stromal cell cul-
tures, indicating that neither activin nor inhibin was syn-
thesised in these cells. Hybridisation occurred only with the
probe for the P-A chain and was restricted to cultures derived
from normal kidney tissue. The presence of P-A mRNA in
human kidney fibroblasts has not been reported before
(Meunier et al., 1988).
Bioassay using MLCCL-64 cellsfor detection ofTGF-P
activity
To test further the production of active TGF-P by prostate-
derived stromal cell cultures, we used a bioassay with the
TGF-p-sensitive mink lung carcinoma cell line MLCCL-64.
For comparison, the inhibition of PC-3 cell growth by TGF-
P and partially purified inhibitor was also determined. Both
TGF-PI and TGF-P2 were found to inhibit PC-3 cell growth
(Figure 6a). The concentrated solution of inhibitor had to be
diluted ten times to cause an inhibition similar to that of
5 ng ml-' TGF-,B. As might be expected, TGF-P1I and TGF-
132 had a stronger antiproliferative effect on MLCCL-64 cells
than on PC-3 cells (Figure 6b). However, no significant
inhibition of MLCCL-64 cell growth was observed with CM
or with serial dilutions of the partially purified inhibitor.
These data demonstrate that CM-mediated inhibition of PC-
3 cell growth was not caused by TGF-P. Those findings were
confirmed by the highly sensitive [3H]thymidine incorporation
assay on MLCCL-64 cells that appeared to be slightly
stimulated by fresh-frozen CM as well as by partially purified
p-EIF (not shown). However, after prolonged storage (more
than 2 months) CM tended to gain some inhibitory activity
on both cell types when compared with fresh basal medium,
probably as a result of activation of latent TGF-P.
Using this [3H]thymidine incorporation assay on MLCCL-
64 cells increasing amounts of active TGF-13 were also
detected in samples from basal medium as well as from CM
after heating (Figure 4b).
Effects ofTGF-P neutralising antibodies
In order to confirm the absence of active TGF-P, we per-
formed MTT tests on PC-3 cells using neutralising antibodies
against TGF-P1 and TGF-P2. As shown in Figure 7a, prein-
cubation ofTGF-P1 with polyclonal antibodies raised against
purified TGF-P1 neutralised its effect completely. Those
It1 02 A r1
5-A (5.6kb)
P-B (4.2 kb)
(3.5 kb)
TGF-1 (2.5 kb)
(X (1.6kb)
Actin (2.2kb)
Figure 5 Northern blot analysis of total RNA from stromal cell
cultures derived from Wilms' tumour (lane 1), tissues from two
different BPH patients (lanes 2 and 4) and normal kidney tissue
(lane 3). Sertoli cells, known to express inhibin mRNAs, were
used as a control (c). P-A, P-B, activin/inhibin subunits; a, inhibin
a-subunit.
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antibodies, however, did not cause a significant decline in the
level of inhibition induced by partially purified p-EIF. Tests
with TGF-,B2-specific antibodies gave essentially the same
results (Figure 7b). These findings, again, demonstrated that
the putative inhibitor present in the CM was different from
TGF-P. Since PC-3 cells are known to secrete predominantly
TGF-P2 in their CM (Ikeda et al., 1987), we were also
interested in the influence of TGF-P2 antibodies on the
growth of PC-3 cells themselves. Figure 7b shows that these
antibodies did not improve the growth of the PC-3,
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Figure 6 Serial dilutions of TGF-P1 (O) TGF-P2 (*) and par-
tially purified inhibitor (0) on (a) PC-3 cells and (b) MLCCL-64
cells, tested in the MTTassay. TGF-ps were diluted in MEM
containing 0.1% bovine serum albumin. The serial (2-fold) dilu-
tions of inhibitor (P40-50) were prepared in MEM. Highest con-
centration: 12501g ml-'. Results are given as percentage of
growth of control cultures grown in fresh basal medium. Bars
= s.d.
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Figure 7 Effect of TGF-P neutralising antibodies on growth
inhibition induced by prostatic stromal cell derived inhibitor. (a)
TGF-P1 antibodies. (b) TGF-132 antibodies. Solutions of immune
serum (I), non-immune serum (N), TGF-P1 (T in a) and TGF-P2
(T in b) were prepared in MEM containing 0.1% bovine serum
albumin (M). Preparations of partially purified inhibitor (P) were
diluted in the same solution. TGF-P and stromal cell inhibitor
were mixed with equal amounts of antibody and all samples were
preincubated for I h at 37°C before they were added to the test.
Bars = s.d. (n = 6). *T + I is significantly different from T and
not different from I; **P + I is not significantly different from P
and different from I.
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indicating that there was no active 'autocrine' TGF-P2 pres-
ent that could be recognised by the antibodies.
Discussion
Following the observation that epithelium loses its growth
capacity when separated from the stroma (Franks et al.,
1970), it has become increasingly clear that both autocrine
and paracrine factors produced by epithelial and stromal
cells play an important role in the local control of prostatic
growth. It has been demonstrated that urogenital sinus
mesenchyme plays a major role in the (androgen-induced)
development of the gland (Cunha et al., 1987); subsequently
it was shown that these interactions may have retained their
integral role in the adult prostate (Cunha et al., 1987; Chung
et al.,1991a,b). These observations indicated that the develop-
ment of cancer and other disease states is likely to involve a
loss of coordination or other alterations in such interactions.
McNeal (1978) suggested the reversion of prostatic stroma to
an 'embryological state' inducing inappropriate epithelial
proliferation in benign prostatic hyperplasia. Tenniswood
(1987) hypothesised the existence of two growth-stimulating
factors and one growth inhibitor, produced in stroma and
epithelium, that control growth and differentiation. He also
suggested that the development of BPH may be caused by
continuously elevated expression of one or more of these
factors. Indeed, several epithelial cell growth-promoting pep-
tides have been identified in the prostate and in prostate-
derived epithelial cell cultures (Thompson, 1990; Story,
1991), and some of these have been positively identified as
being produced (also) by stromal cells, suggesting a role in
stromal-epithelial interactions (Story et al., 1989; Djakiew et
al., 1991; Gleave et al., 1992).
The fact, however, that prolonged androgen administration
to castrated animals does not induce the gland to grow
beyond its predetermined size (Sugimura et al., 1986),
together with the observation that withdrawal of androgens
decreases epithelial cell number only in the in vivo situation
where stroma is present (Isaacs, 1984; McKeehan et al.,
1984), suggests a role for stromally derived epithelial cell
growth inhibitors. To date, the only well-studied epithelial
cell growth inhibitor identified in the prostate is TGF-P
(Wilding, 1991). The transforming growth factor P family
includes a group of closely homologous proteins (Massague,
1987). Three distinct molecular forms, designated TGF-31,
TGF-P2 and TGF-P3, have been identified in mammals (Bar-
nard et al., 1990). Most cells, including stromal cells, secrete
TGF-P as a latent complex which can be activated by treat-
ment with heat, acid or proteases such as plasmin (Lawrence
et al., 1985; Rowley, 1992b). Also, commercially available
sera have been shown to contain latent TGF-P (Childs et al.,
1982). The expression and activation appears to be influenced
by steroid hormones (Kyprianou and Isaacs, 1989; Mar-
tikainen et al., 1990), as was shown also for urogenital sinus
mesenchyme (Rowley, 1992b). The expression of TGF-P
mRNA in human prostatic tissue (TGF-P1 and -P2; Mori et
al., 1990) as well as in rat ventral prostate (TGF-p1; Kyp-
rianou and Isaacs, 1989) has been demonstrated by Northern
blot analyses. Recent immunohistochemical studies of
diseased human prostates demonstrated TGF-P1 immun-
oreactivity in both epithelial and mesenchymal cells (Truong
et al., 1993). In vitro studies with TGF-13I have shown that
this factor inhibits proliferation of prostatic carcinoma cell
lines PC-3, DU 145 and LNCaP (Schuurmans et al., 1988;
Wilding et al., 1989; Goldstein et al., 1991), while PC-3 cells
were found to secrete latent TGF-1 (predominantly 02) in the
culture medium (Ikeda et al., 1987; Danielpour et al., 1989).
Two other members of the TGF-P family of growth and
differentiation factors are activin and inhibin (Massague,
1987). Both factors have previously been shown to compete
for TGF-P binding to pituitary tumour cells (Cheifetz et al.,
1988). Furthermore, TGF-p-like properties of activin in
developmental biology were recently demonstrated (Van den
Eijnden-Van Raaij et al., 1990b). Both activin and inhibin
can interfere with cell growth (Gonzales-Manchon and Vale,
1989; Hedger et al., 1989), and inhibin-like proteins have
been demonstrated in seminal plasma and prostate tissue
(Shah and Sheth, 1991).
Using a two-layer soft-agar system, we previously observed
an inhibition of the clonal growth of prostatic carcinoma cell
lines by prostatic stromal cells. It was shown to be mediated
by a diffusible factor present in the CM (Kooistra et al.,
1991, 1995a), which we referred to as p-EIF (Konig et al.,
1987). In the present work we investigated the possibility that
p-EIF is identical to one of the well-known epithelial growth
inhibitors mentioned above. Since TGF-,B mRNAs were exp-
ressed in our stromal cell cultures (Figure 5), active TGF-P
could have been produced (among latent TGF-,B) by the
stromal cells (Rowley, 1992b). On the other hand, the active
fraction of inhibitor might consist of 'fibroblast-activated'
latent TGF-P, for instance, present in the serum (Childs et
al., 1982; Antonelli-Orlidge et al., 1989). Our data show that
p-EIF has several properties in common with TGF-P, includ-
ing reversibility of inhibition (Hebert and Birnbaum, 1989;
Kooistra et al., 1995a) and sensitivity to trypsin and reducing
agents. Elaboration of inhibiting activity under acidic condi-
tions (Figure 3c) is known to occur in solutions containing
latent TGF-,B (Lawrence et al., 1985). From the observations
described above we may conclude that latent TGF-P was
derived from the serum present during conditioning and/or
secreted by the stromal cells themselves. Since activation was
observed in stability tests performed on concentrated par-
tially purified inhibitor preparations, we have to conclude
that latent TGF-P co-precipitated with p-EIF at 40-50%
ammonium sulphate saturation. Similar considerations apply
to heat treatment (Figure 3d). However, the tendency of the
inhibitor to lose its inhibiting capacity upon heating
(significant at 56°C and 70°C), was probably obscured at
higher temperatures by the generation of active TGF-,B from
the solution (Figure 4). This observation appeared to disc-
riminate our inhibitor from the TGF-,B family of growth-
modulating factors. However, since the sample is not highly
purified yet, we realise that the possibility of co-precipitation
of active inhibitor adhering to other denatured products
cannot be ruled out. Nevertheless, further strong biological
and immunological evidence was provided that p-EIF is
different from these inhibitors. In particular, the observation
that the antiproliferative effect of semipurified p-EIF was not
altered by P1 and P2 neutralising antibodies (Figure 7) ruled
out the presence of active TGF-P1 and 132 in these prepara-
tions.
Absence of inhibition of MCF-7 cells (Kooistra et al.,
1995a), sensitive to all three TGF-ps (Knabbe et al., 1987;
Graycar et al., 1989), supported this conclusion. In addition,
the lack of an inhibitory effect on MLCCL-64 cell growth
(Figure 6) argued strongly against the action of TGF-p1, P2
or P3 (Graycar et al., 1989).
Recently, growth inhibition of a bladder carcinoma cell
line as well as PC-3 cells by serum-containing medium condi-
tioned by a fibroblastoid cell strain subcultured from
urogenital sinus was reported (Rowley and Tindall, 1987;
Rowley, 1992a). Physicochemical properties of the reported
factor (UGIF) suggest that it is different from that found in
the present study. However, it should be kept in mind that in
both cases tests were performed on crude preparations
limiting the value of these observations. Limonti et al. (1992)
reported the antiproliferative effect of luteinising hormone-
releasing hormone (LHRH) agonists on LNCaP cells.
Specific binding sites were demonstrated, while receptor as
well as peptide levels were thought to be negatively regulated
by androgens. However, since stromal cell-derived inhibitory
activity was not lost upon dialysis (cut-off 3.5 kDa), these
peptides can be ruled out as candidates for the reported
inhibitory activity on the basis of their molecular size.
Interferons (IFNs) have also been shown to inhibit growth of
prostatic epithelial cells (Deshpande et al., 1989; Goldstein et
al., 1991; Okutani et al., 1991), and, among other cell types,
fibroblasts have been recognised as a rich source of interferon
(arbitrarily called IFN-P) (Vilcek et al., 1987). We believe,
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however, this is not a likely candidate either, for two reasons.
First, untreated fibroblasts produce subeffective concentra-
tions of IFN, and only treatment with 'inducers' (e.g. virus
infection or double-stranded RNA chains) leads to the secre-
tion of detectable amounts of IFN-P in the CM. Second,
LNCaP cells were shown not to be inhibited by IFN-,B
(Goldstein et al., 1991), while we demonstrated inhibition of
anchorage-dependent and anchorage-independent growth of
LNCaP cells by prostatic stromal cell CM.
In conclusion, the data presented in this paper demonstrate
that adult prostate-derived stromal cells cultured from neop-
lastic lesions produce a unique factor, tentatively called
'prostate-derived epithelium inhibiting Factor' (p-EIF). On
the basis of its spectrum of biological activity as well as its
physicochemical and immunological properties, p-EIF can be
discriminated from previously described growth inhibitors,
including the TGF-p-related proteins inhibin and activin
(Massague, 1987), and from interferon beta (Goldstein et al.,
1991). The organ-specific production and the lack of inhibi-
tion on all non-prostatic epithelial cell lines tested, emphasise
the importance of this inhibitor (Kooistra et al., 1995a). It
would be very interesting to investigate whether this factor is
the major 'brake' on the prostate, controlling epithelial cell
proliferation and thus prostatic size. Several aspects concern-
ing the production of p-EIF are still under investigation.
Preliminary data suggest that serum-derived factors are
required for optimal production and/or secretion. We failed
to demonstrate significant effects of steroids (testosterone,
dihydrotestosterone or oestradiol) in this respect however.
Further knowledge of the factors influencing its production
will facilitate purification and characterisation. Antibodies
raised against the purified factor would provide us with an
excellent tool for studying its role in normal physiology and
its possible involvement in the development of neoplasia.
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